BNP Paribas Financial Markets Has $16.10 Million Holdings in Viridian Therapeutics, Inc. $VRDN

BNP Paribas Financial Markets boosted its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 113.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 517,398 shares of the company’s stock after buying an additional 275,091 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.54% of Viridian Therapeutics worth $16,101,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of VRDN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Viridian Therapeutics by 1.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock worth $669,000 after purchasing an additional 876 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Viridian Therapeutics by 33.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,231,092 shares of the company’s stock worth $16,595,000 after acquiring an additional 310,998 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Viridian Therapeutics by 12.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 130,570 shares of the company’s stock worth $1,760,000 after acquiring an additional 14,788 shares during the period. Envestnet Asset Management Inc. bought a new position in shares of Viridian Therapeutics during the 2nd quarter worth about $187,000. Finally, Creative Planning bought a new position in shares of Viridian Therapeutics during the 2nd quarter worth about $179,000.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on VRDN shares. Royal Bank Of Canada raised their price objective on shares of Viridian Therapeutics from $30.00 to $34.00 and gave the stock an “outperform” rating in a report on Wednesday, May 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Viridian Therapeutics in a report on Monday, April 20th. Stifel Nicolaus set a $39.00 price target on shares of Viridian Therapeutics in a report on Wednesday, May 13th. Needham & Company LLC reissued a “buy” rating and set a $32.00 price target on shares of Viridian Therapeutics in a report on Tuesday, May 5th. Finally, Wells Fargo & Company cut their price target on shares of Viridian Therapeutics from $29.00 to $20.00 and set an “equal weight” rating for the company in a report on Tuesday, March 31st. Twelve equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Viridian Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $36.14.

Viridian Therapeutics Trading Down 4.8%

VRDN opened at $15.78 on Friday. The company has a debt-to-equity ratio of 0.10, a current ratio of 15.15 and a quick ratio of 15.15. The company has a market cap of $1.63 billion, a price-to-earnings ratio of -4.75 and a beta of 0.90. The firm has a 50 day simple moving average of $16.61 and a 200 day simple moving average of $25.75. Viridian Therapeutics, Inc. has a fifty-two week low of $13.18 and a fifty-two week high of $34.29.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.16. The business had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.04 million. Viridian Therapeutics had a negative net margin of 490.31% and a negative return on equity of 80.19%. Viridian Therapeutics’s revenue for the quarter was up 95.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.87) earnings per share. On average, sell-side analysts anticipate that Viridian Therapeutics, Inc. will post -3.87 earnings per share for the current year.

Insider Transactions at Viridian Therapeutics

In other news, Director Fairmount Funds Management Llc acquired 1,176,470 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average price of $17.00 per share, for a total transaction of $19,999,990.00. Following the completion of the acquisition, the director owned 5,090,928 shares in the company, valued at $86,545,776. This trade represents a 30.05% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 2.40% of the company’s stock.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.